Sorafenib, sunitinib may pose cardiovascular risk

October 13, 2015
Sorafenib, sunitinib may pose cardiovascular risk

(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.

Sekwon Jang, M.D., from the Inova Dwight and Martha Schar Cancer Institute in Fairfax, Virginia, and colleagues used the Surveillance, Epidemiology, and End Results-Medicare database to identify patients who were 66 years or older and were diagnosed with (RCC) from 2000 to 2009. The incidence of cardiovascular adverse events was analyzed through December 2010.

The researchers found that 171 of 670 patients who received sunitinib or sorafenib had cardiovascular events. The incidence rates for and cardiomyopathy, , and stroke were 0.87, 0.14, and 0.14 per 1,000 person-days, respectively. There was an increased risk of cardiovascular events associated with sunitinib or sorafenib use (hazard ratio [HR], 1.38), especially for stroke (HR, 2.84), compared with the 788 patients diagnosed with advanced RCC from 2007 to 2009 who were eligible but did not receive either drug. Patients aged 66 to 74 years at diagnosis had the highest increased risk of stroke associated with use of the drugs.

"Sunitinib and sorafenib might be associated with an increased risk of and particularly stroke," conclude the authors.

Two authors report financial ties to the pharmaceutical industry.

Explore further: Nonalbuminuric CKD ups cardiovascular morbidity in T1DM

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Nonalbuminuric CKD ups cardiovascular morbidity in T1DM

August 31, 2015
(HealthDay)—Nonalbuminuric chronic kidney disease is associated with increased risk of cardiovascular disease and all-cause mortality, but not renal outcomes, in patients with type 1 diabetes, according to a study published ...

Anemia linked to adverse outcomes in atrial fibrillation

March 4, 2015
(HealthDay)—For patients with atrial fibrillation receiving anticoagulant treatment, the presence of anemia is associated with increased risk of thromboembolic events, bleeding complications, and mortality, according to ...

Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

February 24, 2015
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was ...

Research suggests stroke risk up with beta-blockers in select patients

October 8, 2014
(HealthDay)—For patients without prior myocardial infarction (MI) with no heart failure, β-blocker use is not associated with lower cardiovascular events, and there may be an increased risk of stroke for patients without ...

Death of partner associated with increased risk of heart attack, stroke

February 24, 2014
The risk of heart attack or stroke is increased in the 30 days after a partner's death.

Modest relation between HbA1c, cardiovascular events

September 4, 2015
(HealthDay)—For patients with type 2 diabetes, hemoglobin A1c (HbA1c) is not significantly associated with cardiovascular events, regardless of clinical manifestation of vascular disease, according to a study published ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.